Rua Bioscience Limited — Director's Dealing 2025

Nov 20, 2025

==> picture [120 x 46] intentionally omitted <==

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

ToNZX Limited; and
Name of listed issuer:		Rua Bioscience Limited(Rua)
Date this disclosure made:		21-Nov-25
Date of last disclosure:		14-Nov-25
Director or senior managergiving disclosure
Full name(s):		Paul Naske
Name of listed issuer:		Rua Bioscience
Name of related body corporate (if applicable):		N/A
Position held in listed issuer:		Chief Executive
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:		Ordinaryshares
Nature of the affected relevant interest(s):		Shareholder
For that relevant interest-
Number held in class before acquisition or disposal:		189,872
Number held in class after acquisition or disposal:		1,562,372
Current registered holder(s):		Paul Naske
Registered holder(s)once transfers are registered:		Paul Naske
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:		N/A
Class of underlyingfinancialproducts:		N/A
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):		N/A
A statement as to whether the derivative is cash settled or physically settled:		N/A
Maturitydate of the derivative(if any):		N/A
Expirydate of the derivative(if any):		N/A
Theprice specified in the terms of the derivative(if any):		N/A
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by the		N/A
value of the underlying financial products:
_For that derivative,- _
Parties to the derivative:		N/A
If the director or senior manager is not a party to the derivative, the nature of
the relevant interest in the derivative:		N/A
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:		1

Details of transactions requiring disclosure

Details of transactions requiring disclosure
Date of transaction:	d:	20-Nov-25
Nature of transaction:		Allocation of shares under LR 4.6.1 to reward CEO for past performance and incentivise futureperformance.
Name of anyotherpartyorparties to the transaction(if known):		Rua Bioscience Limited
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:		$38,430 being 1,372,500 shares at $0.028per share.
Number of financialproducts to which the transaction related:		1,372,500
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—
Whether relevant interests were acquired or disposed of duringa closedperio		No
Whether prior written clearance was provided to allow the acquisition or disposal toproceed duringthe closedperiod:		N/A
Date of the prior written clearance(if any):		N/A

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products: Nature of relevant interest: For that relevant interest,- Number held in class: Current registered holder(s): For a derivative relevant interest,- Type of derivative:

Ordinary Shares Registered holder

Details of derivative

Details of derivative
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):		N/A
A statement as to whether the derivative is cash settled or physically settled:		N/A
Maturity date of the derivative (if any):		N/A
Expiry date of the derivative (if any):		N/A
The price's specified terms (if any):		N/A
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlyingfinancialproducts:		N/A
For that derivative relevant interest,-
Parties to the derivative:		N/A
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:		N/A

Certification

Certification
I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure byallpersons for whom it is made.
Signature of person authorised to sign on behalf of director or officer:
Date of signature:		21/11/2025
Name and title of authorisedperson:		Paul Naske,CEO